HY05350 for mesothelin-positive advanced solid tumors

A Multicenter, Open-label Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Clinical Efficacy of HY05350 for Injection in Patients With MSLN-positive Advanced Solid Tumors

This trial will test HY05350 to see if it is safe and can help adults with mesothelin-positive advanced solid tumors after standard treatments have failed.

Quick facts

• Phase: Phase1; Phase2
• Study type: Interventional
• Enrollment: 262 (estimated)
• Ages: 18 Years to 75 Years
• Sex: All
• Sponsor: Sichuan Huiyu Pharmaceutical Co., Ltd (Industry-sponsored)
• Drugs / interventions: chemotherapy, immunotherapy
• Locations: 1 site (Beijing, Beijing Municipality)
• Trial ID: NCT07083323 on ClinicalTrials.gov

What this trial studies

This is a multicenter, open-label Phase I/II trial with a dose-escalation part followed by a dose-expansion part. Part 1 will identify the maximum tolerated dose and recommended Phase 2 dose while characterizing safety and pharmacokinetics. Part 2 will enroll patients with mesothelin-positive measurable disease to gather preliminary anti-tumor efficacy data. All participants must have confirmed mesothelin-positive tumors and adequate organ function and will provide tumor tissue for biomarker testing.

Who should consider this trial

Good fit: Adults aged 18–75 with pathologically confirmed mesothelin-positive advanced solid tumors, ECOG 0–1, adequate organ function, and prior standard therapies exhausted are the intended candidates.

Not a fit: Patients without mesothelin expression, poor performance status, active major organ dysfunction, or who cannot undergo required biopsies are unlikely to benefit.

Why it matters

Potential benefit: If successful, HY05350 could offer a new treatment option that shrinks tumors or prolongs disease control for patients with mesothelin-positive advanced solid tumors.

How similar studies have performed: Other mesothelin-targeted approaches, including antibody-drug conjugates and cell therapies, have shown promising signals in early trials but results vary by agent and tumor type, so the approach has precedent but is not yet proven.

Eligibility criteria

Inclusion Criteria:

1. Aged ≥18 years and ≤75 years at the time of signing the informed consent form, regardless of gender.
2. Investigator-assessed expected survival period ≥3 months.
3. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 1.
4. Patients with cytologically or pathologically confirmed advanced solid tumors who have failed standard treatment.
5. Subjects enrolled in the dose escalation stage must have evaluable tumor lesions, and subjects enrolled in the dose expansion stage must have at least one measurable tumor lesion (based on RECIST 1.1).
6. Participant must have adequate main organ function.
7. Agree to provide archived pathological tissues or fresh biopsy tumor tissues for detection of related markers such as MSLN and Programmed cell death ligand 1 (PD-L1) expression levels, and MSLN expression is positive.
8. Female subjects of childbearing potential must have a negative serum pregnancy test within 7 days before the first drug administration, and be willing to use effective contraceptive methods to prevent pregnancy and have no plans to donate eggs during the study period and for 6 months after the last drug administration. Male subjects must agree to have no plans to donate sperm and use effective contraceptive methods during the study period and for 6 months after the last drug administration. Postmenopausal women must have been amenorrheic for at least 12 months to be considered non-childbearing.

Exclusion Criteria:

1. Received radiotherapy, chemotherapy, endocrine therapy, biological therapy, immunotherapy and other anti-tumor therapies within 4 weeks before the first drug administration.
2. Received other investigational drugs or participated in interventional medical device studies within 4 weeks before the first drug administration.
3. Had received or planned to receive live/attenuated vaccines or mRNA vaccines within 4 weeks before screening.
4. Pregnant or lactating women.
5. Subjects with adverse events caused by previous anti-tumor therapy that remained \> Grade 1 (based on CTCAE 5.0) before the first drug administration.
6. Subjects with a history of ≥ Grade 3 immune-related adverse events or who discontinued immunotherapy due to irAE of any grade.
7. Subjects with primary central nervous system (CNS) tumors, symptomatic CNS metastases, meningeal metastases, or a history of epilepsy are excluded.
8. Subjects who underwent major surgery on vital organs (excluding biopsy) within 4 weeks before the first drug administration, experienced significant trauma, or require major elective surgery during the trial.
9. Subjects with a history of tissue or organ transplantation.
10. Subjects who had severe infections within 4 weeks before the first drug administration.
11. Positive human immunodeficiency virus test.
12. Active hepatitis B, untreated chronic hepatitis B, or chronic hepatitis B that is treated but uncontrolled.
13. Subjects with active Hepatitis C virus(HCV) infection;
14. Positive treponema pallidum antibody and confirmed positive by diagnostic test;
15. Subjects with untreated or ongoing tuberculosis.
16. Known severe allergic history, or known allergic reactions to macromolecular protein preparations/antibodies or any component of the investigational drug.
17. History of active autoimmune diseases or a history of autoimmune diseases with potential for recurrence.
18. Subjects who received systemic glucocorticoids or other immunosuppressants within 14 days before the first drug administration.
19. History of non-infectious pneumonia requiring glucocorticoid treatment or current interstitial lung disease.
20. History of severe cardiovascular and cerebrovascular diseases.
21. Subjects with thrombosis or bleeding risk.
22. Known history of psychoactive substance abuse or drug use that is considered to affect study compliance.
23. Except for the tumor enrolled in the study, subjects with other active malignant tumors within 1 year before the first drug administration.
24. Uncontrolled pleural effusion, pericardial effusion, or ascites requiring drainage.
25. Subjects deemed unsuitable for participation by the investigator.

Where this trial is running

Beijing, Beijing Municipality

• Peking University Cancer Hospital — Beijing, Beijing Municipality, China (Recruiting)

Study contacts

• Study coordinator: Chun Wan

Conditions Advanced Solid Tumor